Malignant mesothelioma <i>in situ</i>

Churg, Andrew; Hwang, Harry C.; Tan, Lawrence; Qing, Gefei; Taher, Altaf; Tong, Amy; Bilawich, Ana Maria; Đačić, Sanja

doi:10.1111/his.13468

Cited by 55 publications

(56 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the different truncated and mutated forms of cytoplasmic BAP1 tested thus far have been biologically inactive . Because benign cells always show BAP1 nuclear staining, the absence of BAP1 nuclear staining is a specific and reliable marker to distinguish mesothelioma from benign atypical mesothelial hyperplasia at its earliest stages of development . Overall, approximately 70% of epithelial and 50% of sarcomatoid mesotheliomas contain somatic BAP1 mutations, resulting in an absence of BAP1 nuclear staining .…”

Section: Diagnosis and Evaluationmentioning

confidence: 99%

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone

Adusumilli

Alexander

et al. 2019

CA A Cancer J Clinicians

362

488

View full text Add to dashboard Cite

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment. CA Cancer J Clin 2019;69:402-429.

show abstract

Section: Diagnosis and Evaluationmentioning

confidence: 99%

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone

Adusumilli

Alexander

et al. 2019

CA A Cancer J Clinicians

362

488

View full text Add to dashboard Cite

show abstract

“…1,15 Nonetheless, MIS remained controversial until recently, due to lack of agreement on the cell of origin in mesothelioma, lack of clear and uniform diagnostic criteria, difficulty with interpretation because of similarities with benign mesothelial hyperplasia, and the belief of some that MIS was not a premalignant lesion but instead surface spread of concurrent invasive disease not present in that particular biopsy (even if radiology was normal). 7,16,17 Recently, advances in molecular techniques have resulted in renewed interest in the concept, recognising its potential for early diagnosis in some patients. We have reported loss of BRCA1-associated protein-1 (BAP1) in some effusions and biopsies of patients without invasive tumour at the time who developed invasive tumour later.…”

Section: Introductionmentioning

confidence: 99%

“…18 Preliminary data from Churg et al have identified molecular alterations of BAP1 and CDKN2A in MIS, both of which have been implicated in the pathogenesis of MM. 16,19 Additionally, the same group studied expression of methylthioadenosine phosphorylase (MTAP) in MIS. MTAP has been suggested as an alternative for CDKN2A as a diagnostic marker for MM in surgical and cytology samples as it is frequently co-deleted owing to their close proximity.…”

Section: Introductionmentioning

confidence: 99%

Malignant mesothelioma in situ: diagnostic and clinical considerations

2020

View full text Add to dashboard Cite

“…7 Furthermore, the in situ stage of mesothelioma has recently been a focus of great interest for understanding the progression of this disease. 8,9 Mesothelioma in situ is associated with a high risk of developing invasive mesothelioma. However, the progression to invasive disease typically occurs over a relatively prolonged period of time, making timely curable interventions possible.…”

Section: Introductionmentioning

confidence: 99%

Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma

Kinoshita

Hamasaki

Matsumoto

et al. 2020

Pathology International

View full text Add to dashboard Cite

BRCA1‐associated protein 1 (BAP1) or methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) or 9p21 fluorescence in situ hybridization (FISH) are useful for the diagnosis of malignant pleural mesothelioma (MPM). However, the effect of these assays on the diagnostic yield of effusion cytology in MPM cases with suspicious cytomorphology or the diagnostic challenges in BAP1 or MTAP IHC have not been fully elucidated. Two cohorts of cytologic preparations obtained from pleural effusions were examined: MPM cases in cohort 1 were used to evaluate whether BAP1 or MTAP IHC or 9p21 FISH increase the diagnostic yield of effusion cytology; cohort 2 included cases suspicious for MPM, to which BAP1 or MTAP IHC was applied to clarify the challenges in the clinical assessment of these assays. In cohort 1 (n = 28), either assay elevated 62.5% of class II or III cases to class V. In cohort 2 (n = 139), 21.7% of BAP1 immunocytochemistry in smears and 10.6% of BAP1 IHC and 9.4% of MTAP IHC in cell blocks, were identified to be challenging. The application of genomic‐based assays increased the diagnostic yield of effusion cytology in the diagnosis of MPM. However, diagnostic challenges limit the application of these assays in some cases.

show abstract

Malignant mesothelioma in situ

Cited by 55 publications

References 15 publications

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Malignant mesothelioma in situ: diagnostic and clinical considerations

Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma

Contact Info

Product

Resources

About